Sifeng Qu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sifeng Qu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Xia Sun
Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
4 shared publicationsHuangwei Huang
Department of Urology, Cheeloo College of Medicine, Qilu Hospital, Shandong University, Jinan, China
3 shared publicationsJing Qin
Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
3 shared publicationsQiushuang Ma
Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
3 shared publicationsYahong Cheng
Department of Pharmacology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
3 shared publications- Jun Chen
Department of Urology, Qilu Hospital of Shandong University, Jinan, China
2 shared publications
Latest Publications
- 26 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-11
Patient-Derived Organoids for Predicting Chemotherapy Response in Bladder Cancer: A Multicenter, Real-world Validation Study
Responses to chemotherapeutic agents vary substantially among patients with bladder cancer. The lack of preclinical models that accurately predict the clin
- 26 October 2026
- Published by Springer Nature in Annals of Surgical Oncology
- p. 1-11
Patient-Derived Organoids for Predicting Chemotherapy Response in Bladder Cancer: A Multicenter, Real-world Validation Study
Responses to chemotherapeutic agents vary substantially among patients with bladder cancer. The lack of preclinical models that accurately predict the clin
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
Identification of novel gene-based risk score for prognosis in prostate cancer
Tumor carcinogenesis and progression result from multiple genetic alterations in tumor cells. However, reliable biomarkers for prostate cancer classification remain limited, often leading to either overtreatment or inadequate treatment. Additionally, effective biomarkers for selecting patients who may benefit from immunotherapy are still lacking. Using data from TCGA-PRAD, we established gene selection criteria to develop a gene-based risk score. We identified a novel gene risk panel comprising six genes (SSTR1, CA14, HJURP, KRTAP5-1, VGF, and COMP) for prostate cancer risk classification. Patients in the high-risk group were associated with poor prognosis. The gene panel exhibited significantly enhanced predictive accuracy for progression-free survival compared to conventional clinicopathological parameters, including T stage, N stage, primary Gleason score, and secondary Gleason score. High-risk patients exhibited a higher tumor mutation burden. Notably, immune activity of CD8 + T cells, NK cells, and the type II IFN response was significantly lower in the high-risk group, indicating a more immunosuppressive environment. Furthermore, a nomogram combining the gene-based risk score with T stage and histological grade was constructed. The expression of genes in the gene-based risk score was further validated using clinical samples, and VGF was found to play a significant role in prostate cancer progression. The nomogram could serve as a valuable biomarker for distinguishing between high-risk and low-risk of PFS prostate cancer patients and for selecting patients who might benefit from immunotherapy.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
Open AccessIdentification of novel gene-based risk score for prognosis in prostate cancer
Tumor carcinogenesis and progression result from multiple genetic alterations in tumor cells. However, reliable biomarkers for prostate cancer classification remain limited, often leading to either overtreatment or inadequate treatment. Additionally, effective biomarkers for selecting patients who may benefit from immunotherapy are still lacking. Using data from TCGA-PRAD, we established gene selection criteria to develop a gene-based risk score. We identified a novel gene risk panel comprising six genes (SSTR1, CA14, HJURP, KRTAP5-1, VGF, and COMP) for prostate cancer risk classification. Patients in the high-risk group were associated with poor prognosis. The gene panel exhibited significantly enhanced predictive accuracy for progression-free survival compared to conventional clinicopathological parameters, including T stage, N stage, primary Gleason score, and secondary Gleason score. High-risk patients exhibited a higher tumor mutation burden. Notably, immune activity of CD8 + T cells, NK cells, and the type II IFN response was significantly lower in the high-risk group, indicating a more immunosuppressive environment. Furthermore, a nomogram combining the gene-based risk score with T stage and histological grade was constructed. The expression of genes in the gene-based risk score was further validated using clinical samples, and VGF was found to play a significant role in prostate cancer progression. The nomogram could serve as a valuable biomarker for distinguishing between high-risk and low-risk of PFS prostate cancer patients and for selecting patients who might benefit from immunotherapy.
- Open Access
- 23 December 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2442067
Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and differentiation, as well as high tumorigenicity and drug resistance. In prostate cancer (PCa), it is difficult to kill these cells using androgen signaling inhibitors and chemotherapy drugs. Consequently, the residual prostate cancer stem cells (PCSCs) mediate tumor recurrence and progression. This review aims to provide a comprehensive and up-to-date overview of PCSCs, with a particular emphasis on potential therapeutic strategies targeting these cells. After searching in PubMed and Embase databases using 'prostate cancer' and 'cancer stem cells' as keywords, studies related were compiled and examined. In this review, we detail the origin and characteristics of PCSCs, introduce the regulatory pathways closely related to CSC survival and stemness maintenance, and discuss the link between epithelial-mesenchymal transition, tumor microenvironment and tumor stemness. Furthermore, we introduce the currently available therapeutic strategies targeting CSCs, including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy. Lastly, we summarize the limitations of current CSC research and mention future research directions. A deeper understanding of the regulatory network and molecular markers of PCSCs could facilitate the development of novel therapeutic strategies targeting these cells. Previous preclinical studies have demonstrated the potential of this treatment approach. In the future, this may offer alternative treatment options for PCa patients.
- 23 December 2024
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2442067
Open AccessStemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and differentiation, as well as high tumorigenicity and drug resistance. In prostate cancer (PCa), it is difficult to kill these cells using androgen signaling inhibitors and chemotherapy drugs. Consequently, the residual prostate cancer stem cells (PCSCs) mediate tumor recurrence and progression. This review aims to provide a comprehensive and up-to-date overview of PCSCs, with a particular emphasis on potential therapeutic strategies targeting these cells. After searching in PubMed and Embase databases using 'prostate cancer' and 'cancer stem cells' as keywords, studies related were compiled and examined. In this review, we detail the origin and characteristics of PCSCs, introduce the regulatory pathways closely related to CSC survival and stemness maintenance, and discuss the link between epithelial-mesenchymal transition, tumor microenvironment and tumor stemness. Furthermore, we introduce the currently available therapeutic strategies targeting CSCs, including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy. Lastly, we summarize the limitations of current CSC research and mention future research directions. A deeper understanding of the regulatory network and molecular markers of PCSCs could facilitate the development of novel therapeutic strategies targeting these cells. Previous preclinical studies have demonstrated the potential of this treatment approach. In the future, this may offer alternative treatment options for PCa patients.
- Open Access
- 9 March 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1108004
Overexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance
Background: As distinct marker of proliferating cells, chromatin assembly factor-1 (CAF-1) was critical in DNA replication. However, there is paucity information about the clinical significance, functions and co-expressed gene network of CHAF1A, the major subunit in CAF-1, in cancer.Methods: Bioinformatic analysis of CHAF1A and its co-expression gene network were performed using various public databases. Functional validation of CHAF1A was applied in breast cancer.Results: Overexpression of CHAF1A was found in 20 types of cancer tissues. Elevated expression of CHAF1A was positively correlated with breast cancer progression and poor patients’ outcome. The analysis of co-expression gene network demonstrated CHAF1A was associated with not only cell proliferation, DNA repair, apoptosis, but cancer metabolism, immune system, and drug resistance. More importantly, higher expression of CHAF1A was positively correlated with immunosuppressive microenvironment and resistance to endocrine therapy and chemotherapy. Elevated expression of CHAF1A was confirmed in breast cancer tissues. Silencing of CHAF1A can significantly inhibit cell proliferation in MDA-MB-231 cells.Conclusion: The current work suggested that overexpression of CHAF1A can be used as diagnostic and poor prognostic biomarker of breast cancer. Higher expression of CHAF1A induced fast resistance to endocrine therapy and chemotherapy, it may be a promising therapeutic target and a biomarker to predict the sensitivity of immunotherapy in breast cancer.
- 9 March 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1108004
Open AccessOverexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance
Background: As distinct marker of proliferating cells, chromatin assembly factor-1 (CAF-1) was critical in DNA replication. However, there is paucity information about the clinical significance, functions and co-expressed gene network of CHAF1A, the major subunit in CAF-1, in cancer.Methods: Bioinformatic analysis of CHAF1A and its co-expression gene network were performed using various public databases. Functional validation of CHAF1A was applied in breast cancer.Results: Overexpression of CHAF1A was found in 20 types of cancer tissues. Elevated expression of CHAF1A was positively correlated with breast cancer progression and poor patients’ outcome. The analysis of co-expression gene network demonstrated CHAF1A was associated with not only cell proliferation, DNA repair, apoptosis, but cancer metabolism, immune system, and drug resistance. More importantly, higher expression of CHAF1A was positively correlated with immunosuppressive microenvironment and resistance to endocrine therapy and chemotherapy. Elevated expression of CHAF1A was confirmed in breast cancer tissues. Silencing of CHAF1A can significantly inhibit cell proliferation in MDA-MB-231 cells.Conclusion: The current work suggested that overexpression of CHAF1A can be used as diagnostic and poor prognostic biomarker of breast cancer. Higher expression of CHAF1A induced fast resistance to endocrine therapy and chemotherapy, it may be a promising therapeutic target and a biomarker to predict the sensitivity of immunotherapy in breast cancer.
- Open Access
- 21 February 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1156392
Editorial: The development of lethal prostate cancer
Editorial: The development of lethal prostate cancer
- 21 February 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1156392
Open AccessEditorial: The development of lethal prostate cancer
Editorial: The development of lethal prostate cancer
- Open Access
- 30 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (52) , e32529
An uncommon perineal embryonal rhabdomyosarcoma in adult: A case report
Rationale: Embryonal rhabdomyosarcoma (ERMS) is a major subtype of rhabdomyosarcoma, mainly affect children. There is seldom report for perineal ERMS in adults, since its rare location and the age. Patient concerns: A 20-year old male adult was admitted due to the perineal mass. Diagnoses: Diagnosis by histopathological examination of the biopsy sample was ERMS. Magnetic resonance imaging showed the tumor was found in the perineal region, with metastasis to pelvic cavity, right testis, lymph nodes and bone. Interventions: The patient received Isophosphamide and Epirubicin for 4 cycles, followed by Irinotecan and Vindesine Sulfate for 2 cycles, then cisplatin, Dacarbazine and Apatinib for 3 cycles. Outcome: The patient showed no response to chemotherapy. Lessons: Perineal ERMS in adults is very rare. There is still no standard therapy for adult ERMS. Personalized therapy might be promising treatment for each individual.
- 30 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (52) , e32529
Open AccessAn uncommon perineal embryonal rhabdomyosarcoma in adult: A case report
Rationale: Embryonal rhabdomyosarcoma (ERMS) is a major subtype of rhabdomyosarcoma, mainly affect children. There is seldom report for perineal ERMS in adults, since its rare location and the age. Patient concerns: A 20-year old male adult was admitted due to the perineal mass. Diagnoses: Diagnosis by histopathological examination of the biopsy sample was ERMS. Magnetic resonance imaging showed the tumor was found in the perineal region, with metastasis to pelvic cavity, right testis, lymph nodes and bone. Interventions: The patient received Isophosphamide and Epirubicin for 4 cycles, followed by Irinotecan and Vindesine Sulfate for 2 cycles, then cisplatin, Dacarbazine and Apatinib for 3 cycles. Outcome: The patient showed no response to chemotherapy. Lessons: Perineal ERMS in adults is very rare. There is still no standard therapy for adult ERMS. Personalized therapy might be promising treatment for each individual.
- Open Access
- 23 February 2022
- Published by Springer Nature in Research Square
Overexpression of CHAF1A correlates with poor prognosis and tumor immunosuppressive microenvironment and resistance to treatment in cancer
Background: As distinct marker of proliferating cells, chromatin assembly factor-1 (CAF-1) was critical in DNA replication. CHAF1A, the major subunit in CAF-1 complex, has been shown to be highly expressed in some cancer types. However, there is paucity information about the clinical significance, molecule functions and co-expressed gene network of CHAF1A in breast cancer. Methods: Bioinformatic analysis of CHAF1A and its co-expression gene network were performed using various public databases. Results: Abnormally high expression of CHAF1A was found in 20 types of cancer tissues. Elevated expression of CHAF1A was positively correlated with breast cancer progression and poor patient outcome. Co-expression gene network analysis indicated that CHAF1A was associated with not only cell proliferation, DNA repair, apoptosis, but also cancer metabolism, immune system, drug resistance and so on. More importantly, higher expression of CHAF1A was positively correlated with immunosuppressive microenvironment and resistance to endocrine therapy and chemotherapy. Conclusions: The current study indicates that elevated expression of CHAF1A can be used as diagnosis and poor prognosis biomarker of breast cancer. Although higher expression of CHAF1A induced fast resistance to endocrine therapy and chemotherapy, it may be a potential therapeutic target and biomarker to predict the sensitivity of immunotherapy in breast cancer patients.
- 23 February 2022
- Published by Springer Nature in Research Square
Open AccessOverexpression of CHAF1A correlates with poor prognosis and tumor immunosuppressive microenvironment and resistance to treatment in cancer
Background: As distinct marker of proliferating cells, chromatin assembly factor-1 (CAF-1) was critical in DNA replication. CHAF1A, the major subunit in CAF-1 complex, has been shown to be highly expressed in some cancer types. However, there is paucity information about the clinical significance, molecule functions and co-expressed gene network of CHAF1A in breast cancer. Methods: Bioinformatic analysis of CHAF1A and its co-expression gene network were performed using various public databases. Results: Abnormally high expression of CHAF1A was found in 20 types of cancer tissues. Elevated expression of CHAF1A was positively correlated with breast cancer progression and poor patient outcome. Co-expression gene network analysis indicated that CHAF1A was associated with not only cell proliferation, DNA repair, apoptosis, but also cancer metabolism, immune system, drug resistance and so on. More importantly, higher expression of CHAF1A was positively correlated with immunosuppressive microenvironment and resistance to endocrine therapy and chemotherapy. Conclusions: The current study indicates that elevated expression of CHAF1A can be used as diagnosis and poor prognosis biomarker of breast cancer. Although higher expression of CHAF1A induced fast resistance to endocrine therapy and chemotherapy, it may be a potential therapeutic target and biomarker to predict the sensitivity of immunotherapy in breast cancer patients.